Company intelligence / Profile preview
Ostia Sciences Inc.
Toronto, Ontario, Canadaostiasciences.ca ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Ostia Sciences has developed a phosphorylated lantibiotic technology with targeted antimicrobial and pro-immunity benefits. Its lead candidate, SALI‑10, an oral probiotic, will enter clinical trials in early 2025 for respiratory and oral disease indications. The company recently secured over CAD $1 million in seed funding and full IP transfer from the University of Toronto to accelerate development and scale-up. No published clinical results yet; first-in-human studies are pending.
- Therapeutic areas
- PulmonologyOther
- Modalities
- Oral probioticsBiotherapeutics (phosphorylated lantibiotic technology)Microbiome-based therapeutics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
University of Toronto (spinout origin, IP assignment)
Beyond the preview
Go deeper on Ostia Sciences Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ostia Sciences Inc..